blood
Bayer promotes Xarelto benefits
June 15, 2015Sales and Marketing Bayer, Eliquis, Xarelto, blood, law suits, rivaroxaban
Bayer HealthCare is releasing new evidence to suggest that the risk of taking its best-selling blood thinner Xarelto is outweighed …
Novartis drug to treat iron overload gets US nod
March 31, 2015Sales and Marketing FDA, Novartis, blood, deferasirox, exjade, iron, jadenu
Novartis’ iron overload drug Jadenu has been given the green light by US regulators to treat patients with a serious …
Daiichi-Sankyo blood drug gets FDA nod
January 12, 2015Sales and Marketing BMS, Daiichi Sankyo, Daiichi-Sankyo, FDA, Pfizer, Pradaxa, atrial fibrillation, blood, savaysa
The US Food and Drug Administration has shown Daiichi-Sankyo’s anti-clotting drug Savaysa the green light to reduce the risk of …
NHS to get world’s most expensive drug
November 27, 2014Sales and Marketing Alexion, NICE, aHUS, beauchamp, blood, eculizumab, soliris
UK health watchdog NICE has recommended Alexion’s Soliris for patients with the rare disease atypical haemolytic uremic syndrome (aHUS). Soliris …
Pfizer/BMS blood thinner gains new licence
August 22, 2014Sales and Marketing BMS, DVT, Eliquis, Pfizer, Pradaxa, Xarelto, blood, warfarin
Pfizer and Bristol-Myers Squibb have been handed a much-needed lift after its new blood thinner Eliquis gained a licence extension …
Reprieve for AstraZeneca as US drops drug investigation
August 19, 2014Sales and Marketing AstraZeneca, Brilinta, US, blood, justice, plato
The US Justice Department has pulled a controversial investigation into AstraZeneca’s pivotal clinical trial after finding no wrongdoing. The inquiry …
FDA approves Gilead’s blood cancer drug
July 24, 2014Research and Development, Sales and Marketing Cancer, FDA, Gilead, blood, follicular lymphoma and small lymphocytic lymphoma, lymphocytic leukaemia, sovaldi, zydelig
The Food and Drug Administration has approved Gilead Sciences new treatment Zydelig (idelalisib) to treat three types of blood cancer. …
BMJ investigation raises new concerns over Pradaxa
July 24, 2014Medical Communications, Research and Development, Sales and Marketing BMJ, Boehringer, Channel 4, Pradaxa, blood, warfarin
An investigation by The BMJ has raised fresh concerns about Boehringer’s top-selling blood thinner Pradaxa (dabigatran) and the regulatory decisions …
Boehringer blood cancer drug scores in Phase II
July 9, 2014Research and Development, Sales and Marketing Boehringer, blood, giotrif, leukaemia, volasertib
Less than a year after securing its first cancer drug on the market with Giotrif, Boehringer has taken another decisive …
Lilly’s Efient tipped for expanded NICE approval
June 20, 2014Sales and Marketing Effient, Efient, FDA, NHS, blood, lilly, longston, thinner
Eli Lilly’s anti-platelet drug Efient has been given the nod by UK healthcare watchdog NICE for more widespread use, pending …
Pradaxa gets DVT indication
June 6, 2014Sales and Marketing Boehringer, DVT, Pradaxa, blood, dabigatran etexilate, thinner
Pradaxa has been given approval in Europe to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) just a week …
Boehringer settles US lawsuits
May 29, 2014Medical Communications, Sales and Marketing Boehringer, Pradaxa, US, blood, lawsuits, warfarin
Boehringer Ingelheim has sought to bring to an end around 4,000 legal cases which have been brought against the company …
Alexion ‘concerned’ over NICE draft
March 4, 2014Sales and Marketing NICE, aHUS, alexia, blood, eculizumab, soliris
Alexion Pharmaceuticals UK has expressed ‘concern’ that NICE has not yet allowed its rare disease treatment Soliris to be formally …
GSK submits new Promacta licence
March 3, 2014Sales and Marketing GSK, NICE, Promacta, Revolade, blood, eltrombopag
GlaxoSmithKline is seeking a new licence for its blood disorder drug Promacta in patients with severe aplastic anaemia. Specifically, the …
Bayer ‘disappointed’ with FDA
February 18, 2014Sales and Marketing ACS, Bayer, Xarelto, blood, rivaroxaban
Bayer HealthCare has expressed its dismay after the Food and Drug Administration once again rejected further indications for the company’s …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
